Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c

Piper Remains Constructive on Intra-Cellular Therapies (ITCI) Following Q3 Report; Affirms at 'Overweight'

November 9, 2016 12:39 PM EST

Piper Jaffray affirms Intra-Cellular Therapies (Nasdaq: ITCI) with an Overweight rating and $22 price target following Q3 results and update issued earlier Wednesday.

Analyst Charles Duncan noted the following: It ended 3Q16 with $413M in cash available for operations, which should fund the... More